What were the clinical trial results with Avastin?
In both first- and second-line MCRC, Avastin-based therapy has consistently demonstrated superior survival results over IV 5-FU–containing chemotherapy alone. • Avastin plus IFL (Study 2107) resulted in a 4.7-month (30%) increase in median overall survival vs IFL alone in previously untreated patients. The survival benefit associated with Avastin was observed early in treatment and persisted throughout the course of the trial. Median duration of Avastin therapy was 40.4 weeks1,2 • Avastin plus IV 5-FU/LV (combined analysis) resulted in a 3.3-month (23%) increase in median overall survival vs a “combined control” of IV 5-FU/LV or IFL alone in previously untreated patients4 • Avastin plus FOLFOX4 (Study E3200) resulted in a 2.2-month (20%) increase in median overall survival vs FOLFOX4 alone.
